RxDoctor Payments Data

Asim Ulusarac, MD

Psychiatry · Kansas City, MONPI 1730151671

Payments from drug & device makers

$11,995in general payments, 2019–2025

Across 764 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$895
  • Johnson & Johnson$870
  • Sunovion Pharmaceuticals Inc.$755
  • Tris Pharma Inc$571
  • plus $5K from 26 others

What the payments were for

  • Food & beverage$11,943100%
  • Education$520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,995 in reported general payments places this provider in the 90th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$71,510
Medicare patients
195
Services billed
589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole26$45,176
VyvanseLisdexamfetamine Dimesylate49$19,216
TrileptalOxcarbazepine13$14,371
Bupropion XlBupropion Hcl314$7,670
Duloxetine Hcl306$7,546
Lisdexamfetamine Dimesylate48$7,183
Aripiprazole196$6,882
Venlafaxine Hcl ErVenlafaxine Hcl205$4,827
Trazodone Hcl352$3,100
Lamotrigine OdtLamotrigine12$2,948
Alprazolam548$2,658
Asenapine Maleate12$2,640
Desvenlafaxine Succinate ErDesvenlafaxine Succinate33$2,587
Lamotrigine136$2,586
Escitalopram Oxalate322$2,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$1,465$45,17626 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$334$19,21649 claims
Almatica Pharma LLCSertraline Hcl$26$971122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →